As of Jul 22
| -0.0096 / -1.48%|
The 2 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.63, with a high estimate of 3.50 and a low estimate of 1.75. The median estimate represents a +309.90% increase from the last price of 0.64.
The current consensus among 2 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.